Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

301 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-04-07

Study Completion Date

2024-01-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine if family members of patients with xeroderma pigmentosum (XP) have various abnormalities, including: skin abnormalities; nervous system abnormalities, such as hearing problems; skin, eye, or internal cancers, or other changes. XP is a rare inherited disease that involves an inability to repair damage to cell DNA (genetic material). It can affect several organ systems, including the skin, eye, nervous system, and bones. Patients have a more than thousand-fold increase in frequency in all major skin cancers.

Parents of patients with XP are carriers of the abnormal XP gene. Other family members may also be carriers of the abnormal XP gene. Carriers do not develop the disease themselves; symptoms develop only in children who have inherited the faulty gene from both parents. This study will try to clarify the genetic basis for XP and to understand the increased frequency of cancer in the disease.

XP patients who have been evaluated at the NIH Clinical Center and their relatives are eligible for this study. Newly diagnosed XP patients are also eligible. Spouses of relatives will also be included as control subjects.

Patients and their family members will undergo some or all of the following procedures:

* Parental permission to review the child s relevant medical records and pathology material from treatments or surgery for cancer or other related illnesses
* Medical history and physical examination, with particular attention to the skin and possible eye, hearing or neurological examinations
* Photographs to document skin and other physical findings
* Nuclear medicine scans to evaluate the brain and nervous system
* X-rays of the skull or other parts of the body
* Nervous system testing with an electroencephalogram (EEG), electroretinogram (ERG), electromyogram (EMG) or nerve conduction velocity measurement
* Collection of blood and skin samples for gene studies
* Establishment of cell lines from collected blood or tissues to study DNA repair, skin cancer, cancers related to XP, immune defects, and related studies.
* Biopsy (surgical removal of a small piece of tissue) of suspicious skin lesions for examination under a microscope
* Collection of a cheek cell sample, obtained by twirling a soft brush against the inside of the cheek
* Collection of a hair sample for microscopic examination and composition analysis
* Surgery to treat skin cancers or other lesions

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis

NCT00055029

Retinoschisis

ACTIVE_NOT_RECRUITING

Genetic Studies of X-linked Lymphoproliferative Disease

NCT00359411

X-Linked Lymphoproliferative Disease Lymphoproliferative Disease Genetic Diseases, X-Linked

COMPLETED

Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnancy: A Deep Phenotype Study

NCT05548881

Cardiovascular Phenotype Metabolic Phenotype Hypertensive Disease +2 more

WITHDRAWN

Identification of Mutations Responsible for Rare Familial Skin Diseases by Next Generation Sequencing

NCT02509650

Familial Lipomatosis Very Rare Dermatologic Diseases

UNKNOWN

Do Your Genes Put You at a Higher Risk of Developing Mesothelioma

NCT01590472

Mesothelioma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Xeroderma Pigmentosum (XP) is a rare, recessive disorder with a more than 1000-fold increase in the frequency of all major skin cancers in association with defective DNA repair. The risk of skin and other cancers among normal appearing XP heterozygote individuals has not been fully studied. We plan to study the family members from XP families with known DNA repair gene mutations to determine if heterozygote carriers of XP disease mutations are at an increased risk of developing cancer. For controls we will compare XP heterozygotes to their non-carrier blood relatives and spouses and to the Surveillance, Epidemiology and End Results (SEER) rates. For this purpose, blood, skin or buccal cells will be obtained from all available relatives for DNA or RNA mutation analysis. Cancer confirmation will be accomplished through review of pathology reports, medical records and death certificates. In addition, willing family members will be clinically examined to determine current cancer status. Individuals who are determined to be heterozygous carriers of XP DNA repair gene disease mutations in these families by mutation analysis or by pedigree will be compared to non-carrier relatives and spouses with respect to history of any type of cancer. We will also focus on skin cancer and cancer of the nervous system since the risks of these cancers are elevated among the XP homozygotes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Xeroderma Pigmentosum Basal Cell Carcinoma Squamous Cell Carcinoma Melanoma Skin Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients with XP

No interventions assigned to this group

2

Family members from XP families with known DNA repair gene mutations

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Members of the XP families where the proband has previously been evaluated at the Clinical Center or is newly diagnosed under other approved protocols (primarily 99-C-0099) are eligible to participate in this study. Families with XP patients of any age (excluding neonates), gender or race are eligible for this study.

* On referral, patients with XP and families of XP patients will be considered for inclusion in the study if the proband has clinical documentation of features of XP and laboratory determination of the DNA repair defect. All relatives of XP patients including spouses are eligible to participate. A spouse of a blood relative of a patient with xeroderma pigmentosum would also be eligible.
* Ability of patient or Legally Authorized Representative (LAR) to sign a written informed consent document